Management of HIV infection in patients with cancer receiving chemotherapy

Clinical Infectious Diseases

Volumn 59, Issue 1, 2014, Pages 106-114

  Torres, Harrys A ^a   Mulanovich, Victor ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

AIDS; antiretrovirals; cancer; HIV

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DARUNAVIR; DEXAMETHASONE; DOLUTEGRAVIR; DOXORUBICIN; EFAVIRENZ; ELVITEGRAVIR; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; LAMIVUDINE PLUS ZIDOVUDINE; MARAVIROC; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PREDNISONE; PROTEINASE INHIBITOR; RALTEGRAVIR; RAPAMYCIN; RILPIVIRINE; RITUXIMAB; RNA DIRECTED DNA POLYMERASE INHIBITOR; TACROLIMUS; TIPRANAVIR; UNINDEXED DRUG; VINCRISTINE; ZIDOVUDINE; ANTIRETROVIRUS AGENT;

ARTICLE; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; DRUG METABOLISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG CANCER; NEOPLASM; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROPHYLAXIS; COMPLICATION; DRUG INTERACTION; DRUG THERAPY; HIV INFECTIONS; NEOPLASMS; PROCEDURES;

ANTI-RETROVIRAL AGENTS; ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; DRUG THERAPY; HIV INFECTIONS; HUMANS; NEOPLASMS;

EID: 84904012016     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu174     Document Type: Article

References (49)

1. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet 2013; 382:1525-33.
2. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescent GL.pdf. Accessed 7 November 2013.
3. Schneider E, Whitmore S, Glynn KM, Dominguez K, Mitsch A, McKenna MT. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years-United States, 2008. MMWR Recomm Rep 2008; 57:1-12.
4. Bonnet F, Burty C, Lewden C, et al. Changes in cancer mortality among HIV-infected patients: the Mortalite 2005 Survey. Clin Infect Dis 2009; 48:633-9.
5. Monforte A, Abrams D, Pradier C, et al. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008; 22:2143-53.
6. Powles T, Robinson D, Stebbing J, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 2009; 27:884-90.
7. Deeken JF, Pantanowitz L, Dezube BJ. Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook. Curr Opin Oncol 2009; 21:445-54.
8. Deeken JF, Tjen ALA, Rudek MA, et al. The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis 2012; 55:1228-35.
9. Mitsuyasu RT. Non-AIDS-defining malignancies in HIV. Top HIV Med 2008; 16:117-21.
10. Antinori A, Cingolani A, Alba L, et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001; 15:1483-91.
11. Mounier N, Katlama C, Costagliola D, Chichmanian RM, Spano JP. Drug interactions between antineoplastic and antiretroviral therapies: implications and management for clinical practice. Crit Rev Oncol Hematol 2009; 72:10-20.
12. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1-207; quiz CE1-4.
13. Rudek MA, Flexner C, Ambinder RF. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol 2011; 12:905-12.
14. Montoto S, Shaw K, Okosun J, et al. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol 2012; 30:4111-6.
15. Berretta M, Di Benedetto F, Dal Maso L, et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients. Anticancer Drugs 2013; 24:212-8.
16. Levine AM, Noy A, Lee JY, et al. Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047. J Clin Oncol 2013; 31:58-64.
17. Castillo JJ, Echenique IA. Rituximab in combination with chemotherapy versus chemotherapy alone in HIV-associated non-Hodgkin lymphoma: a pooled analysis of 15 prospective studies. Am J Hematol 2012; 87:330-3.
18. Blazy A, Hennequin C, Gornet JM, et al. Anal carcinomas in HIVpositive patients: high-dose chemoradiotherapy is feasible in the era of highly active antiretroviral therapy. Dis Colon Rectum 2005; 48: 1176-81.
19. Pakkala S, Chen Z, Rimland D, et al. Human immunodeficiency virusassociated lung cancer in the era of highly active antiretroviral therapy. Cancer 2012; 118:164-72.
20. Simonelli C, Zanussi S, Cinelli R, et al. Impact of concomitant antiblastic chemotherapy and highly active antiretroviral therapy on human immunodeficiency virus (HIV) viremia and genotyping in HIV-infected patients with non-Hodgkin lymphoma. Clin Infect Dis 2003; 37:820-7.
21. Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 2002; 94:1492-9.
22. Wong AY, Marcotte S, Laroche M, et al. Safety and efficacy of CHOP for treatment of diffuse large B-cell lymphoma with different combination antiretroviral therapy regimens: SCULPT study. Antivir Ther 2013; 18:699-707.
23. Torres HA, Rallapalli V, Saxena A, et al. Efficacy and safety of antiretrovirals in HIV-infected patients with cancer [Epub ahead of print]. Clin Microbiol Infect 2014. doi:10.1111/1469-0691.12589.
24. Ratner L, Lee J, Tang S, et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001; 19:2171-8.
25. Vaccher E, Spina M, di Gennaro G, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 2001; 91: 155-63.
26. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373:1352-63.
27. Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008; 197: 1133-44.
28. Hoffmann C, Chow KU, Wolf E, et al. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease. Br J Haematol 2004; 125:455-62.
29. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009; 4: e5575.
30. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387-402.
31. Margolis AM, Heverling H, Pham PA, Stolbach A. A review of the toxicity of HIV medications. J Med Toxicol 2014; 10:26-39.
32. Bower M, Powles T, Stebbing J, Thirlwell C. Potential antiretroviral drug interactions with cyclophosphamide, doxorubicin, and etoposide. J Clin Oncol 2005; 23:1328-9; author reply 9-30.
33. Primeggia J, Timpone JG Jr, Kumar PN. Pharmacologic issues of antiretroviral agents and immunosuppressive regimens in HIV-infected solid organ transplant recipients. Infect Dis Clin North Am 2013; 27:473-86.
34. Reese MJ, Savina PM, Generaux GT, et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos 2013; 41:353-61.
35. Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavirlamivudine for the treatment of HIV-1 infection. N Engl J Med 2013; 369:1807-18.
36. Arribas JR, Eron J. Advances in antiretroviral therapy. Curr Opin HIV AIDS 2013; 8:341-9.
37. Reshef R, Luger SM, Hexner EO, et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med 2012; 367:135-45.
38. Powles T, Imami N, Nelson M, Gazzard BG, Bower M. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. AIDS 2002; 16:531-6.
39. Beumer JH, Venkataramanan R, Rudek MA. Pharmacotherapy in cancer patients with HIV/AIDS. Clin Pharmacol Ther 2014; 95:370-2.
40. Rudek MA, Moore PC, Mitsuyasu RT, et al. A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer [published online ahead of print 28 January 2014]. In: AIDS Malignancy Consortium trial AMC 061. Cancer 2014. doi:10.1002/cncr.28554.
41. Rudek MA, Chang CY, Steadman K, Johnson MD, Desai N, Deeken JF. Combination antiretroviral therapy (cART) component ritonavir significantly alters docetaxel exposure. Cancer Chemother Pharmacol 2014; 73:729-36.
42. Pillai VC, Venkataramanan R, Parise RA, et al. Ritonavir and efavirenz significantly alter the metabolism of erlotinib-an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer. Drug Metab Dispos 2013; 41:1843-51.
43. Deeken JF, Mitsuyasu RT, Little RF. Treating HIV+ patients for non-AIDS-defining cancers (NADCs) in the era of targeted chemotherapy: an AIDS malignancy consortium study of sunitinib in patients on ART. J Clin Oncol 2010; 28(suppl 15):TPS161.
44. Bundow D, Aboulafia DM. Potential drug interaction with paclitaxel and highly active antiretroviral therapy in two patients with AIDS-associated Kaposi sarcoma. Am J Clin Oncol 2004; 27:81-4.
45. Bower M, McCall-Peat N, Ryan N, et al. Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood 2004; 104:2943-6.
46. Segal BH, Freifeld AG, Baden LR, et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 2008; 6: 122-74.
47. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15:1143-238.
48. Zhu Q, Tan DC, Samuel M, Chan ES, Linn YC. Fludarabine in comparison to alkylator-based regimen as induction therapy for chronic lymphocytic leukemia: a systematic review and meta-analysis. Leuk Lymphoma 2004; 45:2239-45.
49. Fraser G, Smith CA, Imrie K, Meyer R. Alemtuzumab in chronic lymphocytic leukemia. Curr Oncol 2007; 14:96-109.